Biodesix Inc. reported total revenue of $21.8 million for the third quarter of 2025, representing a 20% increase compared to the same period in 2024. Gross profit margin for the quarter was 81%, an improvement of 400 basis points year-over-year, attributed to growth in Lung Diagnostic testing, higher average revenue per test, and cost optimization. Operating expenses, excluding direct costs, were $24.7 million, up 10% from the prior year, mainly due to increased sales and marketing costs related to the expansion of the sales team and market awareness initiatives. Non-cash stock compensation expense was $1.1 million, a 30% decrease from the previous year. Biodesix raised its full-year 2025 total revenue guidance to $84-86 million.